ArticleEBioMedicine2026
Modelling the impact of ivermectin-based optimal strategies on malaria control: the role of formulation, coverage, and mosquitocidal efficacy timing.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite wide use of insecticidal nets and indoor spraying, residual malaria transmission persists due to insecticide resistance and mosquito behaviours like early and outdoor biting. Ivermectin (IVM) can kill mosquitoes after blood feeding, regardless of the timing or location of the bite. However, oral IVM's short efficacy duration and required frequent dosing limits epidemiological impact. Using mosquitocidal efficacy data from a long-acting injectable IVM formulation (BEPO® technology), we modelled its effect on malaria transmission, comparing it with oral regimens evaluated in the fields.
methodsWe developed a mathematical model incorporating IVM's pharmacodynamic persistence and stratifying humans by age and sex. Three regimens were evaluated: (i) monthly oral IVM at 3 × 300 μg/kg for 4 months, (ii) monthly oral IVM at 1 × 400 μg/kg for 3 months, and (iii) long-acting BEPO® injection at 0.6 or 1.0 mg/kg. The model includes post-exposure effects on mosquitoes and the target population excludes women of childbearing age or pregnant women, and children under 15 kg. Mosquitocidal efficacy data were derived from published human oral studies and from preclinical studies in livestock (cattle) for injectable formulations.
findingsCampaigns delivering ivermectin are projected to lower clinical prevalence, with slightly greater benefits in Burkina Faso-like seasonal settings when aligned with the transmission peak. Under perennial transmission and 50-90% target population coverage, oral regimens reduced total cases (all ages) by 7-11%, 9-14%, and 24-38% over one year, depending on the regimen and the data source. A single long-acting injectable IVM campaign achieved 16-29%, rising to 33-57%, 48-74%, and 59-78% with two, three, and four campaigns, respectively.
interpretationLong-acting injectable ivermectin offers increased and sustained efficacy and simpler delivery to tackle residual malaria transmission. Phase 1 trials are timely and warranted.
fundingThe African Consortium in Modelling for Effective Vector Control (ACoMVeC) project INV-047049, IMPACT (Unitaid) and Institut de Recherche pour le Développement (IRD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.